Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Braz. j. med. biol. res ; 41(2): 126-134, Feb. 2008. ilus, tab
Article in English | LILACS | ID: lil-474770

ABSTRACT

We compared the cost-benefit of two algorithms, recently proposed by the Centers for Disease Control and Prevention, USA, with the conventional one, the most appropriate for the diagnosis of hepatitis C virus (HCV) infection in the Brazilian population. Serum samples were obtained from 517 ELISA-positive or -inconclusive blood donors who had returned to Fundação Pró-Sangue/Hemocentro de São Paulo to confirm previous results. Algorithm A was based on signal-to-cut-off (s/co) ratio of ELISA anti-HCV samples that show s/co ratio ≥95 percent concordance with immunoblot (IB) positivity. For algorithm B, reflex nucleic acid amplification testing by PCR was required for ELISA-positive or -inconclusive samples and IB for PCR-negative samples. For algorithm C, all positive or inconclusive ELISA samples were submitted to IB. We observed a similar rate of positive results with the three algorithms: 287, 287, and 285 for A, B, and C, respectively, and 283 were concordant with one another. Indeterminate results from algorithms A and C were elucidated by PCR (expanded algorithm) which detected two more positive samples. The estimated cost of algorithms A and B was US$21,299.39 and US$32,397.40, respectively, which were 43.5 and 14.0 percent more economic than C (US$37,673.79). The cost can vary according to the technique used. We conclude that both algorithms A and B are suitable for diagnosing HCV infection in the Brazilian population. Furthermore, algorithm A is the more practical and economical one since it requires supplemental tests for only 54 percent of the samples. Algorithm B provides early information about the presence of viremia.


Subject(s)
Humans , Algorithms , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C Antibodies/blood , Hepatitis C/diagnosis , RNA, Viral/analysis , Blood Donors , Brazil , Cost-Benefit Analysis , Enzyme-Linked Immunosorbent Assay/economics , Hepatitis C/economics , Immunoblotting/economics , Polymerase Chain Reaction/economics , Reagent Kits, Diagnostic/economics , Sensitivity and Specificity
2.
Braz. j. med. biol. res ; 30(6): 749-57, jun. 1997. ilus, tab, graf
Article in English | LILACS | ID: lil-194175

ABSTRACT

The possibility that Ureaplasma urealyticum might play an important role in human infertility was first raised more than 20 years ago, but this association remains speculative. Considering the hypothesis that the pathogenicity of Ureaplasma urealyticum may depend on its serotypes, the clastogenic effcts of different strains of Ureaplasma urealyticum, at concentrations of 10(3) CCU (color changing units)/ml, 10(4) CCU/ml and 10(5) CCU/ml, were evaluated in vitro in short-term cultures of human lyphocytes. Total or partial mitotic inhibition was produced by Ureaplasma urealyticum serotypes 2,3 and 10 independent of the concentration (10(3) CCU/ml, 10(4) CCU/ml or 10 (5) CCU/ml) of the microorganisms employed. In contrast, the clastogenic effects observed with serotypes 1,7 and 12 varied according to the concentration employed in the test. Mitotic alterations were observed in Ureaplasma urealyticum serotypes 5,6,7,8,9,11 and 12. Chromatid gaps (53.0 percent) and chromatid breaks (13.9 percent) were the most frequent types of alterations observed. The results of this in vitro assay demonstrated that the clastogenic effects varied with the Ureaplasma urealyticum serotypes evaluated.


Subject(s)
Humans , Chromatids/ultrastructure , Chromosomes, Human/microbiology , Chromosomes, Human/ultrastructure , Lymphocytes/microbiology , Mitosis/genetics , Mutagens/adverse effects , Ureaplasma urealyticum/pathogenicity , Chromosomes, Human/genetics , Ureaplasma urealyticum/genetics
SELECTION OF CITATIONS
SEARCH DETAIL